Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 266Gynecologic 6Tumor-Agnostic 4Thoracic 4Other solid neoplasm 4Breast 3Dermatologic 2NET 1Head & Neck 1Genitourinary 1Endocrine 1CNS 1

Conditions

Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Cisplatin 630Radiotherapy 339pembrolizumab 329Cetuximab 283Docetaxel 225Radiotherapy, Intensity-Modulated 221Fluorouracil 199Carboplatin 198Paclitaxel 161Nivolumab 145Gemcitabine 125Magnetic Resonance Spectroscopy 99Radiation 91Drug Therapy 86Capecitabine 76toripalimab 74Surveys and Questionnaires 73Surgical Procedures, Operative 72Biopsy 62durvalumab 61Chemoradiotherapy 52Blood Specimen Collection 52Cyclophosphamide 48Specimen Handling 47camrelizumab 46Radiosurgery 46Erlotinib Hydrochloride 46Standard of Care 43130-nm albumin-bound paclitaxel 43tislelizumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Folfox protocol × Head & Neck × Clear all
NCT03526835 2025-01-29

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Merus B.V.

Phase 1/2 Recruiting
523 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡